IRF7 and plasma cell myeloma: Further, RUNX2 has been demonstrated to play a role in T-cell lymphoma, acute myeloid leukemia, and multiple myeloma and to facilitate the response to viral infection through the control of Interferon Regulatory Factor 7 (IRF7) [43,44,45].